Credit Suisse’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q3
Sell
-1,298,100
Closed -$20.5M 4775
2015
Q2
$20.5M Buy
1,298,100
+883,100
+213% +$10.7M 0.02% 822
2015
Q1
$4.51M Buy
415,000
+290,000
+232% +$2.96M ﹤0.01% 1753
2014
Q4
$1.31M Sell
125,000
-279,500
-69% -$2.73M ﹤0.01% 2905
2014
Q3
$3.88M Sell
404,500
-1,055,700
-72% -$10.8M ﹤0.01% 1952
2014
Q2
$16.9M Buy
1,460,200
+1,117,700
+326% +$10.2M 0.01% 1043
2014
Q1
$3.42M Buy
342,500
+112,500
+49% +$1.62M ﹤0.01% 2069
2013
Q4
$3M Buy
+230,000
New +$3.17M ﹤0.01% 2300

Other funds holding RPTP

Credit Suisse's RPTP Position: Q1 2016 in Review

Credit Suisse sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q1 2016, closing a stake of 5,702,042 shares — an estimated $29.6M sold.

Credit Suisse first reported a position in RPTP in Q2 2013 and held it in 11 quarters. The position peaked at $89.8M in Q2 2015. 97 funds tracked by Wall St. Rank hold RPTP as of Q1 2016.

  • Credit Suisse reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q1 2016 after selling out during the quarter.
  • Credit Suisse sold 5,702,042 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q1 2016, an estimated $29.6M.
  • Credit Suisse first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 11 quarters.
  • Credit Suisse's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $89.8M in Q2 2015.
  • 97 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q1 2016.

Based on Credit Suisse's 13F filing for Q1 2016, filed 16 May 2016.